Tri-estarylla Kit
Product Images NDC 70700-121

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tri-estarylla (NDC 70700-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 2

A forest plot showing effect estimates (OR/RR) with confidence intervals from various studies including NICHD Women's Contraceptive Study 2002, French E3N cohort Study 2005, Shanghai Women's Health Study 2009, Nurses' Health Study II 2010, Oxford Family Planning Association Study 2013, and Danish Sex Hormone Register Study 2017. The plot compares ever use and current use data on the horizontal axis representing effect estimates ranging from -1.5 to 2.0.*

FDA Label Image

Chemical Structure 1 (B4ca5260 1e51 4bfd A22e Fd2595f1f812 02)

Chemical structure of norgestimate as shown in the image, depicting the molecular arrangement of this active ingredient found in Tri-Estarylla (norgestimate and ethinyl estradiol) prescription drug kit by Xiromed, LLC.*

FDA Label Image

Chemical Structure 2 (B4ca5260 1e51 4bfd A22e Fd2595f1f812 03)

Chemical structure of ethinyl estradiol, showing its molecular framework with labeled atoms and specific bonds. This depiction relates to the active ingredient in Tri-Estarylla, a prescription drug kit containing norgestimate and ethinyl estradiol by Xiromed, LLC.*

FDA Label Image

Figure (B4ca5260 1e51 4bfd A22e Fd2595f1f812 04)

An effectiveness chart illustrating the relative pregnancy rates among different birth control methods. It categorizes methods from fewer than 1 pregnancy per 100 women per year (implants, injections, intrauterine devices, sterilization) to 85 or more pregnancies per 100 women per year (no birth control). Other methods shown include birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, spermicide, withdrawal, and abstinence during fertile days.*

FDA Label Image

Tri-estar-carton (Tri Estar Carton)

Tri-Estarylla kit packaging label containing norgestimate and ethinyl estradiol tablets USP. It shows dosages of 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.25 mg/0.035 mg. The package includes 3 units of 3x28 tablet blister cards, labeled by Xiromed, LLC, with NDC 70700-121-85. The label indicates prescription usage and includes a barcode and lot/expiration date fields.*

FDA Label Image

Tri-estar (Tri Estar)

Tri-Estarylla oral tablets kit packaging label showing a 28-day pill calendar with days of the week marked, divided into four weeks. The first three weeks have 21 white tablets, and the fourth week has 7 gray tablets. It includes the active ingredients norgestimate and ethinyl estradiol with corresponding dosages. The labeler is Xiromed, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.